Invizius

About:

Invizius provides dialysis treatments and other extra-corporeal treatments for patients.

Top Investors: Mercia Ventures, Mercia Fund Managers, Scottish Enterprise, Jonathan Milner, Downing Ventures

Description:

Invizius offers extra-corporeal treatments for patients that includes dialysis, cardiopulmonary bypass, and ECMO involve the circulation of the patient's blood supply through a machine. Invizius develops H-Guard, an advanced hemocompatible coating capable of preventing foreign body reactions in the blood at the source. Invizius aims to revolutionize dialysis and other extracorporeal treatments.

Total Funding Amount:

11.1M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Edinburgh, Edinburgh, City of, United Kingdom

Founded Date:

2018-01-01

Founders:

Andy Herbert

Number of Employees:

11-50

Last Funding Date:

2024-09-23

IPO Status:

Private

Industries: